Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

Corporate Breaking News

Home : Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

Jul 06 2020	Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors
SUZHOU, China, and ROCKVILLE, Md., July 6, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate...


Source:https://www.prnewswire.com:443/news-releases/ascentage-pharma-announces-clinical-trial-collaboration-agreement-with-msd-to-evaluate-apg-115-in-combination-with-keytruda-pembrolizumab-in-advanced-solid-tumors-301088223.html

Related News
» HKEX Launches 1st Tranche of MSCI Futures Contracts » Gramercy Funds Management and Fintech Advisory Inc. Issue Statement Supporting Argentina Debt Proposal